Feng Wang1, Yuan-Chun Li2, Li-Ping Liu2, Hao-Min Zhang2, Song Tong2. 1. Department of General Surgery, Second Affiliated Hospital, Qiqihar Medical University, Qiqihar, P.R. China. wang39715@163.com. 2. Department of General Surgery, Second Affiliated Hospital, Qiqihar Medical University, Qiqihar, P.R. China.
Abstract
BACKGROUND: Our aim was to retrospectively analyze the relationships between circulating tumor cells (CTCs) and the development of breast cancer, for elucidating the role of CTCs in breast cancer. METHODS: A total of 107 female patients with primary breast cancer and 48 matched healthy female volunteers were recruited. After blood collection, isolation of peripheral blood mononuclear cells (PBMC) was performed followed by the detection of cytokeratin 19 positive (CK19(+) ) and CD44(+) /CD24(-/low) cells, as well as estrogen receptor (ER), progesterone, and CerbB2. Data were analyzed with the SPSS 20.0 software. RESULTS: None of the 48 volunteers were detected with CK19(+) cells in their PBMC, while in 77 patients, 72% of 107 female patients with primary breast cancer, the CK19(+) cells were detected. CK19(+) could also be detected among patients in each grouping by different clinical staging and lymph node metastasis, with statistical differences (all P < 0.05). Further, among the 83 CK19(+) specimens, 32 were also detected with CD44(+) /CD24(-/low) cells. Comparisons of CK19(+) and CD44(+) /CD24(-/low) cells in patients with different clinical features (ER positive vs. ER negative, C-erbB2 positive vs. C-erbB2 negative) and molecular subtypes (triple-negative breast cancer, ER positive, and C-erbB2 positive) showed no obvious difference (all P > 0.05). CONCLUSIONS: Both CTCs and tumor stem cells (TSCs) could be detected in the PBMC of breast cancer patients; besides, positive expression rate of CTCs might be obviously associated with the clinical stage and metastasis. Positive relationship of TSCs and the clinical stage of breast cancer was also proved in this study.
BACKGROUND: Our aim was to retrospectively analyze the relationships between circulating tumor cells (CTCs) and the development of breast cancer, for elucidating the role of CTCs in breast cancer. METHODS: A total of 107 female patients with primary breast cancer and 48 matched healthy female volunteers were recruited. After blood collection, isolation of peripheral blood mononuclear cells (PBMC) was performed followed by the detection of cytokeratin 19 positive (CK19(+) ) and CD44(+) /CD24(-/low) cells, as well as estrogen receptor (ER), progesterone, and CerbB2. Data were analyzed with the SPSS 20.0 software. RESULTS: None of the 48 volunteers were detected with CK19(+) cells in their PBMC, while in 77 patients, 72% of 107 female patients with primary breast cancer, the CK19(+) cells were detected. CK19(+) could also be detected among patients in each grouping by different clinical staging and lymph node metastasis, with statistical differences (all P < 0.05). Further, among the 83 CK19(+) specimens, 32 were also detected with CD44(+) /CD24(-/low) cells. Comparisons of CK19(+) and CD44(+) /CD24(-/low) cells in patients with different clinical features (ER positive vs. ER negative, C-erbB2 positive vs. C-erbB2 negative) and molecular subtypes (triple-negative breast cancer, ER positive, and C-erbB2 positive) showed no obvious difference (all P > 0.05). CONCLUSIONS: Both CTCs and tumor stem cells (TSCs) could be detected in the PBMC of breast cancerpatients; besides, positive expression rate of CTCs might be obviously associated with the clinical stage and metastasis. Positive relationship of TSCs and the clinical stage of breast cancer was also proved in this study.
Authors: John D O'Flaherty; Steven Gray; Derek Richard; Dean Fennell; John J O'Leary; Fiona H Blackhall; Kenneth J O'Byrne Journal: Lung Cancer Date: 2011-12-29 Impact factor: 5.705
Authors: Sophie J Bernelot Moens; Gavin R Schnitzler; Moriah Nickerson; Huiming Guo; Kazutaka Ueda; Qing Lu; Mark J Aronovitz; Heather Nickerson; Wendy E Baur; Ulla Hansen; Lakshmanan K Iyer; Richard H Karas Journal: Circulation Date: 2012-09-20 Impact factor: 29.690
Authors: Sabine Riethdorf; Volkmar Müller; Liling Zhang; Thomas Rau; Sibylle Loibl; Martina Komor; Marc Roller; Jens Huober; Tanja Fehm; Iris Schrader; Jörn Hilfrich; Frank Holms; Hans Tesch; Holger Eidtmann; Michael Untch; Gunter von Minckwitz; Klaus Pantel Journal: Clin Cancer Res Date: 2010-04-20 Impact factor: 12.531
Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Emad A Rakha; Jorge S Reis-Filho; Frederick Baehner; David J Dabbs; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Andrea L Richardson; Stuart J Schnitt; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Sunil Badve; Ian O Ellis Journal: Breast Cancer Res Date: 2010-07-30 Impact factor: 6.466